急性骨髄性白血病（AML、急性骨髄芽球性白血病）では、血液および骨髄が侵されます。未熟な白血球が骨髄に蓄積すると、正常な血液細胞の生成が妨げられてしまいます。これらの細胞はその後血液の中に入り込み、全身に広がります。症状には、疲労感、熱、出血、呼吸困難、体重の減少などが見られます。関係する素因としては、放射線や化学物質に曝されること、喫煙などが挙げられます。治療は化学療法や輸血、移植、薬物療法などで管理します。
目次
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, 2022
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
